JPMorgan Downgrades Akebia Therapeutics (AKBA) to Neutral, After Pharma Study Fails To Meet Endpoints
Tweet Send to a Friend
JPMorgan analyst Eric Joseph downgraded Akebia Therapeutics (NASDAQ: AKBA) ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
